Merck, Moderna say mRNA vaccine and Keytruda lowers the risk of death in melanoma patientsMarket Watch • 12/13/22
Why Merck's $250 Million Investment In Moderna May Have Just Paid OffInvestors Business Daily • 12/13/22
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 TrialAccesswire • 12/13/22
PFIZER VS MODERNA; Which Pharmaceutical Is A Better Stock To Buy Now?The Dog of Wall Street • 12/10/22
FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger KidsZacks Investment Research • 12/09/22
Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of AgeAccesswire • 12/08/22
Moderna Stock Is Yo-Yoing On New Omicron Booster Data — Is It A Buy?Investors Business Daily • 12/07/22
Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting historyCNBC • 12/06/22
Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?Zacks Investment Research • 12/06/22
These Are the Five Best and Worst Performing Healthcare Stocks in October 202224/7 Wall Street • 11/29/22